Sayer has been COO since January 2013 and president since June 2011 at San Diego-based DexCom, which makes continuous glucose monitors. His pedigree includes tenures at Biosensors International (PINK:BSNRY) and MiniMed until its 2001 acquisition by Medtronic (NYSE:MDT), according to a press release.
Gregg, who was president & CEO from 2007 to 2011, when Sayer got the president’s job, said the move is the result of a meticulously planned transition.
"The board of directors and I have tremendous confidence in Kevin’s leadership ability, and we are confident that he will to continue to drive DexCom to new heights of success and to fulfill our potential. Kevin and I share the same vision for DexCom and the patients we serve, a vision we have held together for nearly two decades," he said in prepared remarks. "We have accomplished a great deal over the past several years following Kevin’s appointment as president, and I feel quite comfortable that now is an appropriate time to transition day-to-day leadership to Kevin. This transition will help me continue to direct more of my energies on developing and refining our corporate strategy, and to enhancing DexCom’s external relationships with customers, and key constituents, both domestically and internationally."
"Terry is 1 of the most respected and successful business leaders in medical device technology and remains a passionate advocate for people with diabetes," Sayer added. "Under his guidance, DexCom has accomplished what many other larger and better-resourced companies have failed to do. Terry has built a strong core team, developed a robust technology platform, created a full research and development pipeline and commercialized a game-changing technology that is helping improve the lives of people living with diabetes and I look forward to maintaining a close working relationship with Terry in his new role as executive chairman."
Avinger names new CEO before final medtech IPO of 2014
Avinger, which announced the final medtech IPO of 2014 on Dec. 30, preceded that by naming former Unisyn Medical Technologies CEO Jeff Soinski as its chief executive, succeeding founder Dr. John Simpson. Simpson will stay on as executive chairman, overseeing Avinger’s clinical and R&D programs, according to a press release.
Moraviec is new interim CEO at ConvaTec
ConvaTec said it named EMEA president Paul Moraviec, a Johnson & Johnson (NYSE:JNJ), Abbott (NYSE:ABT) and Bausch & Lomb veteran, as interim CEO while it conducts a search for a permanent replacement for Ken Berger.
Augmenix taps Boston Scientific, Cheetah Medical for CEO, sales veep
Augmenix said it named former Boston Scientific (NYSE:BSX) executive James Pederson as its new CEO and tapped Cheetah Medical‘s Ken Knudson as its global sales & marketing vice president.
Sunshine Heart lures MDT exec Drayton to become CFO
Sunshine Heart said it named former Medtronic executive Claudia Drayton as its new CFO, replacing Jeff Mathiesen, who will stay on as a consultant through the 1st half of the year.
- Cardica sacks R&D veep Knodel
- Endo Health loses legal chief Manogue
- Spine spinout brings Integra exec back into the fold
- Nephros names Mieyal acting CEO, Evans chairman
- BD shuffles Gallagher, Mercurio
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.